These estimates imply that sales are expected to slow, with a forecast revenue decline of 14%, a significant reduction from annual growth of 28% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 20% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Ionis Pharmaceuticals is expected to lag the wider industry.